NCT02343991: Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound

NCT02343991
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: The size of the targeted portion of the patient’s tumor must be less than 2.5 cm in diameter
Exclusions: 
https://ClinicalTrials.gov/show/NCT02343991

Comments are closed.

Up ↑